
Anthony Hagen
Advertisement
Articles by Anthony Hagen


The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
2
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
3
Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk
4
FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera
5
